In addition, recent immunotherapies, such as programmed death-1 receptor (PD-1)/programmed death ligand-1 (PD-L1) pathway blockade, have demonstrated promising effects in various cancers, including NSCLC 7. This evidence concerns the gene CD274 and non-small cell lung carcinoma.